Retension Pharmaceuticals (RTSN) Registration filing summary

Company overview and business model

• Clinical-stage biopharma developer focused on hypertension and cardiovascular diseases; RTN-001 is a once-daily oral PDE-5 inhibitor designed to enhance nitric oxide-cGMP signaling and reach cardiovascular smooth muscle tissue.

• Strategy: advance RTN-001 in hypertension, explore cardiovascular and renal indications and combination treatments, and evaluate partnerships and selective pipeline expansion.

• RTN-001 is exclusively licensed worldwide through Redux; the filing reports ownership of clinical data from nine completed trials conducted by Surface Logix.

Financial performance and metrics

• Net loss was $7.5M in H1 2026 vs. $1.9M in H1 2025; FY 2025 restated net loss was $6.3M vs. $1.9M in FY 2024. No product revenue to date.

• H1 2026 R&D was $6.2M vs. $1.2M in H1 2025; G&A was $1.6M vs. $0.9M. Higher Phase 2b CRO costs and IPO preparation drove increases.

• Cash and equivalents were $13.5M at June 30, 2026 vs. $18.9M at Dec. 31, 2025; accumulated deficit was $15.8M at June 30, 2026.

• FY 2025 statements were restated after $2.3M of CRO advances were expensed before related trial work; the correction reduced FY 2025 R&D, operating expenses and net loss by $2.3M.

• Auditor cited substantial doubt about going concern; management said existing funds did not cover 12 months from interim statement issuance, while offering proceeds plus cash are projected to fund operations for at least 21 months from the prospectus date.

Use of proceeds and capital allocation

• Estimated net proceeds are $33.8M at the assumed $12.00 midpoint, or $39.4M if the over-allotment option is fully exercised.

• Plan: ~$18M to complete the RTN-001 Phase 2b uHTN trial, ~$10M to prepare for and advance planned Phase 3 uHTN work, and the remainder for general corporate purposes and operating expenses.

• Proceeds may also support acquisitions or strategic investments in complementary businesses, products, services or technologies; no material commitments were in place at filing.

• After Phase 2b, substantial additional capital will be needed for planned Phase 3 and later development, regulatory approval and commercialization.